Moolec Science Reports Strong Results from 2025 Safflower Campaign, Validating Commercial-Scale Production
WARWICK, UK / ACCESS Newswire / February 13, 2026 / Moolec Science Limited, a subsidiary of Moolec Science SA (NASDAQ:MLEC), has announced encouraging outcomes from its 2025 U.S. GLASO1 safflower initiative, demonstrating the viability of its plant-based protein production platform. Analysis of the harvested safflower, processed through conventional U.S. crushing facilities, revealed a gamma-linolenic acid (GLA) concentration of approximately 45%, a key indicator of product quality and commercial potential.
The findings, released today, represent a significant operational milestone for Moolec, confirming the compatibility of its genetically engineered safflower with existing U.S. agricultural and processing infrastructure. The 2025 campaign encompassed 1,100 acres cultivated across the United States, yielding an average of roughly 2,200 pounds per acre – a notable 57% increase compared to the approximately 1,400 pounds per acre achieved in 2024. This substantial improvement surpassed internal projections, signaling a successful expansion of the GLASO1 platform.
According to Moolec, the high GLA concentration positions the company favorably within the burgeoning U.S. nutrition and dietary supplement market, where demand is increasingly focused on high-concentration functional lipids, plant-derived traceable ingredients, and scalable production systems.
“The U.S. GLASO1 platform has reached a pivotal juncture,” stated Alejandro Antalich, CEO of Moolec Science. “Achieving approximately 45% GLA concentration at commercial scale confirms that our technology is not only scientifically distinct but also operationally feasible within established U.S. agricultural and processing networks.”
Antalich further emphasized the significance of the results, noting that the GLA concentration achieved by GLASO1 appears to be among the highest reported at commercial scale. He attributed this success to disciplined execution and collaborative partnerships with leading U.S. agricultural and processing operators.
Moolec’s strategy prioritizes scaling platforms with proven, repeatable performance, leveraging existing infrastructure, and maintaining rigorous cost control. The company views the 2025 U.S. GLASO1 campaign as a foundational step toward consistent commercial-scale production and long-term value creation.
Shares of Moolec Science (NASDAQ:MLEC) closed at $5.10, with limited trading volume observed prior to the announcement. The stock currently trades below its 200-day moving average of $41.09, within a 52-week range of $3.08 to $157.05.
About Moolec Science SA
Moolec Science is pioneering the use of engineered plants and microbes to develop scalable protein solutions for the global food system. Combining molecular farming and precision fermentation, the company aims to produce sustainable and commercially viable ingredients, including alternative proteins, bioactive compounds, and nutritional oils. Moolec holds a robust intellectual property portfolio with over 118 patents and operates across the United States, Europe, and South America.
For further information, visit www.moolecscience.com and ir.moolecscience.com.
FAQ
What GLA concentration did Moolec (MLEC) report from the 2025 U.S. GLASO1 crushing on February 13, 2026?
Moolec reported approximately 45% GLA concentration from commercial-scale crushing. According to the company, this result came from the 2025 U.S. GLASO1 campaign and confirms performance through standard U.S. crushing operations at scale.
How large was Moolec's (MLEC) 2025 U.S. GLASO1 safflower campaign and what was the average yield?
The 2025 campaign covered 1,100 acres with an average yield of roughly 2,200 pounds per acre. According to the company, this represented a substantial scale-up from prior deployments and exceeded internal forecasts.
How much did yields improve year-over-year for Moolec's (MLEC) GLASO1 safflower in 2025?
Moolec reported a 57% year-over-year yield increase versus 2024. According to the company, yields rose from about ~1,400 pounds per acre in 2024 to ~2,200 pounds per acre in 2025 across the GLASO1 acreage.
What does the ~45% GLA result mean for Moolec (MLEC)'s market positioning in nutrition and supplements?
The company says the high-concentration result strengthens Moolec's positioning in U.S. nutrition and supplements markets. According to the company, 45% GLA aligns with demand for concentrated, plant-engineered, traceable functional lipids and scalable supply.
Did Moolec (MLEC) confirm compatibility of GLASO1 safflower with existing U.S. processing infrastructure?
Yes—Moolec confirmed compatibility with standard U.S. agricultural and industrial crushing infrastructure. According to the company, GLASO1 performed reliably through harvest and commercial-scale crushing operations during the 2025 campaign.
